GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ventyx Biosciences
Ventyx is a biotech company developing drugs to treat autoimmune diseases. Its stock price is a bet on the success of its clinical pipeline. The chart reflects the high volatility inherent in a sector where lab news is everything.
Share prices of companies in the market segment - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of a range of autoimmune diseases, including psoriasis and Crohn's disease. We classify the company in the Pharmaceuticals (Immunology) segment, which is at the forefront of science. The chart below illustrates the dynamics of this innovative and competitive sector.
Broad Market Index - GURU.Markets
Ventyx Biosciences is a biopharmaceutical company developing oral medications for the treatment of a wide range of autoimmune diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
VTYX - Daily change in the company's share price Ventyx Biosciences
Shares of Ventyx, a biopharmaceutical company, exhibit extreme volatility, as measured by change_co. This indicator reflects sensitivity to clinical trial results. This metric is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
Ventyx Biosciences, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with VTYX, which focuses on immune disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Ventyx Biosciences is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ventyx Biosciences
For Ventyx Biosciences, the year-to-date performance is a story about developing oral drugs for immune diseases. Its 12-month market cap is entirely dependent on clinical trial data. Success in its candidates for psoriasis, Crohn's disease, and ulcerative colitis could make it a leader in a huge and highly competitive market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Ventyx Biosciences, Inc. is a clinical-stage biotech company developing oral medications for the treatment of inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this competitive field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ventyx Biosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ventyx Biosciences
Ventyx Biosciences (Pharma immune) develops drugs to treat immune diseases. The average price (Perf\_Month\_Co) reflects the operating cycles of clinical trials. Any positive or negative data from the testing phases of their key molecules causes strong, but understandable, monthly movements on the chart.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the volatile biotech sector. For Ventyx, a clinical-stage company, it's the backdrop. Its movements show how clinical trial successes and failures across the sector, as well as M&A activity, have impacted investor sentiment and the valuation of companies like Ventyx.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ventyx Biosciences is a clinical-stage biotech company developing drugs to treat immune diseases. Its value is almost entirely dependent on the results of clinical trials. The broader market has little impact on Ventyx shares; their fate is decided in laboratories and clinics, which can lead to sharp movements counter to the market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of immunological diseases. Its weekly stock price is volatile, driven by news of clinical trial results for its candidates.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Ventyx Biosciences is a biopharmaceutical company specializing in drugs for the treatment of autoimmune diseases. The success or failure of clinical trials can lead to sharp rises or falls in its stock. The chart will show how unique its dynamics are, independent of the overall pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ventyx is a clinical-stage biotech. Its shares rely on trial news, not macroeconomics. The chart clearly demonstrates how the company's performance is disconnected from the stock market and follows its own scientific calendar.
Market capitalization of the company, segment and market as a whole
VTYX - Market capitalization of the company Ventyx Biosciences
Ventyx Biosciences' market capitalization reflects investor expectations for its pipeline of immunology treatments. As a clinical-stage company, its volatile price is driven by news of trial results. This is a bet that its small molecules will be competitive with injectable biologics.
VTYX - Share of the company's market capitalization Ventyx Biosciences within the market segment - Pharma immune
Ventyx Biosciences is a clinical-stage biotech company developing small-molecule drugs for the treatment of autoimmune diseases. Its market share reflects the potential of its portfolio. The graph represents a venture bet that its developments will become new standards of treatment.
Market capitalization of the market segment - Pharma immune
The chart below shows the overall value of the biotech sector. Ventyx Biosciences is a company focused on developing oral medications for immune diseases. The potential of this market is enormous. Ventyx is striving to create convenient and effective tablets that can compete with injectable blockbusters, which is what is attracting the attention of investors.
Market capitalization of all companies included in a broad market index - GURU.Markets
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of autoimmune diseases. Its market capitalization reflects the potential of its pipeline. The chart below shows the economic weight of companies developing treatments for immune diseases.
Book value capitalization of the company, segment and market as a whole
VTYX - Book value capitalization of the company Ventyx Biosciences
Ventyx Biosciences' foundation is its intellectual property in a portfolio of small molecules for the treatment of immunological diseases such as psoriasis and Crohn's disease. The chart tells the story of a biotech company that, following promising early-stage trial results, raises significant capital, strengthening its balance sheet for costly late-stage research.
VTYX - Share of the company's book capitalization Ventyx Biosciences within the market segment - Pharma immune
Ventyx Biosciences develops drugs to treat autoimmune diseases. The chart shows its share of actual R&D assets. These are its laboratories where a portfolio of small molecules targeting key inflammatory mechanisms is being developed.
Market segment balance sheet capitalization - Pharma immune
Ventyx Biosciences is a biotech company focused on R&D. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, clearly demonstrating its research-intensive, rather than manufacturing-driven, model.
Book value of all companies included in the broad market index - GURU.Markets
Ventyx Biosciences is a biopharmaceutical company developing drugs for the treatment of autoimmune diseases. Its assets include a portfolio of molecules at various stages of development. A modest stake in BCap_All provides material resources aimed at creating a new generation of drugs to combat psoriasis, arthritis, and other diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ventyx Biosciences
Ventyx Biosciences is a biopharmaceutical company. Its cash premium is a bet on its portfolio of small-molecule drugs for autoimmune diseases, which could provide a convenient alternative to injections.
Market to book capitalization ratio in a market segment - Pharma immune
Ventyx Biosciences is a biotech company developing drugs to treat immune diseases. Its value is based almost entirely on its scientific platform. The chart shows the significant premium to book value that investors are paying for the potential of its precision medicines.
Market to book capitalization ratio for the market as a whole
Ventyx Biosciences is a biotech company developing drugs to treat autoimmune diseases. Its valuation depends almost entirely on the success of clinical trials. This chart demonstrates how market value in the biotech sector can be detached from book value, reflecting hopes for future treatments.
Debts of the company, segment and market as a whole
VTYX - Company debts Ventyx Biosciences
Ventyx Biosciences, a biopharmaceutical company developing small-molecule drugs for the treatment of autoimmune diseases, funds its research with borrowed capital. The debt load reflects the cost of running multiple clinical programs simultaneously, part of its strategy to build a diversified pipeline of candidates.
Market segment debts - Pharma immune
Ventyx Biosciences is a biotech company developing small-molecule drugs for the treatment of autoimmune diseases. Being in the clinical stage, it requires significant capital for research. This chart shows how Ventyx funds its extensive development pipeline, aiming to bring new treatments to a broad range of patients.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ventyx Biosciences
Ventyx Biosciences is a biopharmaceutical company focused on immunology. Its future depends entirely on the success of clinical trials, which require significant funding. This chart shows the company's leverage for R&D, a key indicator of its financial runway and the associated risks.
Market segment debt to market segment book capitalization - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of immune diseases. This chart shows debt trends in their sector. It helps assess how the company finances its extensive clinical pipeline in competitive areas such as psoriasis and Crohn's disease, and how this impacts its financial profile.
Debt to book value of all companies in the market
Ventyx Biosciences is a biopharmaceutical company developing drugs to treat immune diseases. While in clinical trials, Ventyx has no significant revenue and funds its research with equity. This chart of total market debt clearly demonstrates how the financial model of such innovative companies differs from that of mature, leveraged businesses.
P/E of the company, segment and market as a whole
P/E - Ventyx Biosciences
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of immune diseases. This chart shows that the company's valuation is based on the potential of its scientific pipeline. Investors analyze clinical trial data, placing their bets on the development of new, effective drugs.
P/E of the market segment - Pharma immune
This industry chart for biotech companies provides key context for Ventyx Biosciences. It reflects overall high valuations based on breakthrough hopes. Comparisons with this chart help understand whether Ventyx's pipeline for autoimmune disease treatments is considered more or less promising than that of other biotechs in this competitive field.
P/E of the market as a whole
Ventyx Biosciences develops small-molecule drugs for the treatment of a range of immunological diseases. The company has several promising developments in its portfolio. This chart of overall biotech risk appetite shows how investors value companies with multiple shots at goal. Does diversification provide a valuation premium, or are they focusing on the risks of each individual project?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biotechnology company developing oral therapies for a wide range of immune diseases. This chart reflects speculative expectations for its pipeline of candidates. The valuation depends on clinical trial results and the potential of its small molecules to become a convenient alternative to injectable biologics.
%20P%2FE%20Ventyx%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ventyx-Biosciences&v=1772681753828 "Chart of the company's future (projected) P/E Ventyx Biosciences")
Future (projected) P/E of the market segment - Pharma immune
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for immune diseases. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess how the market views its pipeline of candidates and their potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772681753874 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Ventyx Biosciences is a clinical-stage biotechnology company developing small-molecule drugs for the treatment of autoimmune diseases. Given the overall market expectations shown by this chart, Ventyx's business is driven by scientific advances. The success of its clinical trials and the potential of its molecules are the primary factors driving its valuation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772681753899 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ventyx Biosciences
Ventyx Biosciences is a biotech company developing small-molecule drugs to treat a wide range of immune diseases. This chart shows the company's financial performance during clinical trials, where it aims to develop convenient oral alternatives to injectables.
Profit of companies in the market segment - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of immune diseases. This chart shows profitability in the immunology sector. For VTYX, this reflects demand for convenient oral medications for conditions such as psoriasis and Crohn's disease, which is their key competitive advantage.
Overall market profit
Ventyx Biosciences is a biotechnology company developing small-molecule therapeutics for the treatment of a wide range of immune diseases. The company has several promising programs in development. Its valuation is based on the potential of these programs, not on current revenue. This total market return chart does not reflect Ventyx's scientific prospects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ventyx Biosciences
Ventyx Biosciences is a biotechnology company developing small-molecule drugs for the treatment of a wide range of autoimmune diseases. The revenue projections presented here are speculative and depend on the success of its candidates in clinical trials. Analysts are evaluating the potential of its pipeline.
%20profit%20of%20the%20company%20Ventyx%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ventyx-Biosciences&v=1772681753930 "Graph of future (projected) profit of the company Ventyx Biosciences")
Future (predicted) profit of companies in the market segment - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of a wide range of immune diseases. The company's revenue forecast for this sector depends on the success of its extensive pipeline of candidates. This chart reflects analyst expectations for the future market for oral immunology drugs, which could compete with injectables.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772681753945 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing drugs to treat immune diseases. Its future depends on the success of clinical trials. The market revenue forecasts shown here impact the availability of capital for the biotech sector, which is essential for funding R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772681753963 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ventyx Biosciences
Ventyx Biosciences is a biotechnology company developing small-molecule drugs for the treatment of immune diseases. This chart shows the company's speculative valuation, typical during clinical trials. The valuation fluctuates based on news about trial results and the potential of its drugs.
P/S market segment - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing small-molecule therapeutics for a wide range of autoimmune and inflammatory diseases. This chart reflects the average revenue estimate for the sector, providing insight into investor expectations for Ventyx's clinical development and scientific platform.
P/S of the market as a whole
Ventyx Biosciences is a biotech company developing oral medications for the treatment of a wide range of autoimmune diseases, such as psoriasis and Crohn's disease. The company is in clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biotechnology company developing small-molecule therapeutics for the treatment of autoimmune and inflammatory diseases. This chart shows how investors estimate the company's future revenue potential based on the success of its clinical programs.
%20P%2FS%20Ventyx%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ventyx-Biosciences&v=1772681754066 "The graph of the company's future (projected) P/S Ventyx Biosciences")
Future (projected) P/S of the market segment - Pharma immune
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for the treatment of a wide range of inflammatory and autoimmune diseases. This chart reflects the market's assessment of its research pipeline and the potential of its drug candidates to reach major markets.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772681754078 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Ventyx Biosciences is a clinical-stage biotech company developing drugs to treat immune-inflammatory diseases. Their future depends on the success of their trials. This market optimism is vital for VTYX. Access to capital for developing breakthrough, yet expensive, treatments is only possible if investors have faith in the future and science.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772681754111 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for the treatment of a broad range of immune diseases. The company currently has no approved products on the market. This timeline will reflect its future ability to commercialize its research and development in this competitive field.
Sales of companies in the market segment - Pharma immune
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule drugs for the treatment of a range of autoimmune and inflammatory diseases, including psoriasis and Crohn's disease. While in the research stage, the company has not yet generated commercial revenue, but has several promising candidates in development.
Overall market sales
Ventyx Biosciences is a biopharmaceutical company developing oral medications (tablets) for the treatment of a wide range of autoimmune and inflammatory diseases. Its goal is to create convenient and effective alternatives to injectable medications. This total revenue chart includes the healthcare sector, where VTYX is working on developing next-generation drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ventyx Biosciences
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of a wide range of autoimmune diseases, such as psoriasis and Crohn's disease. This graph reflects analyst expectations for the success of its clinical programs in the highly competitive immunology market.
%20sales%20of%20the%20company%20Ventyx%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ventyx-Biosciences&v=1772681754216 "Schedule of future (projected) sales of the company Ventyx Biosciences")
Future (projected) sales of companies in the market segment - Pharma immune
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for the treatment of a wide range of autoimmune diseases. This chart shows forecasts for the entire immunotherapy market. It reflects the enormous need for new, convenient (oral), and effective treatments for conditions such as psoriasis and Crohn's disease.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772681754231 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Ventyx Biosciences, a biotech company focused on treating immune diseases, sees this chart as a reflection of investment appetite for biotech. The stable economic growth projected here provides the capital needed to develop and clinically test oral medications for psoriasis, Crohn's disease, and other conditions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772681754250 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ventyx Biosciences
Ventyx Biosciences is a biotech company developing drugs to treat autoimmune diseases. Currently in the clinical stage, it is entirely focused on research. This chart shows not revenue, but rather the amount of investment in its development pipeline, which is typical for innovative companies in this field.
Market segment marginality - Pharma immune
Ventyx Biosciences is a clinical-stage biotechnology company developing oral therapies for a wide range of autoimmune diseases. This chart reflects the potential of its pipeline. A future strong result will confirm the success of its developments in creating convenient and effective treatments.
Market marginality as a whole
Ventyx Biosciences is a clinical-stage biotechnology company developing drugs to treat immune diseases. Its value is entirely dependent on the success of its research program. This gross profit chart is just a glimpse into the world of oncology research in which Ventyx operates.
Employees in the company, segment and market as a whole
Number of employees in the company Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing orally administered small molecules for the treatment of a wide range of autoimmune and inflammatory diseases. This graphic shows the team of scientists working to create convenient and effective tablets for the treatment of conditions such as psoriasis and Crohn's disease.
Share of the company's employees Ventyx Biosciences within the market segment - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing small molecules to treat a wide range of immune diseases. Its science-intensive approach, based on precision medicine, requires a team of highly skilled chemists and biologists. This graph reflects the concentration of scientific talent required to create a new generation of immunomodulators.
Number of employees in the market segment - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs to treat a wide range of immune-inflammatory diseases, such as psoriasis and Crohn's disease. This graphic shows a team of chemists and biologists creating oral medications to treat diseases currently dominated by injectable biologics.
Number of employees in the market as a whole
Ventyx Biosciences is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory and autoimmune diseases. Their work requires significant funding. General economic stability, reflected by employment trends, is stimulating investment in the biotech sector, allowing Ventyx to advance its promising clinical programs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ventyx Biosciences (VTYX)
Ventyx Biosciences is a biopharmaceutical company developing drugs to treat autoimmune diseases. This chart is a classic example of a research-stage biotech company. Their very high market capitalization per employee reflects investors' belief in the potential of their molecules to become blockbusters. This is a measure of intellectual capital, not physical capital.
%20of%20the%20company%20Ventyx%20Biosciences%20(VTYX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ventyx-Biosciences-VTYX&v=1772681754483 "Chart of market capitalization per employee (in thousands of dollars) of the company Ventyx Biosciences (VTYX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing drugs to treat autoimmune diseases. Its market capitalization is based on the potential of its pipeline of molecules. This chart shows how investors evaluate the company's scientific potential relative to its research team compared to other players in the sector.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772681754494 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of immune diseases. This metric reflects the potential of its pipeline and shows how investors view its ability to create convenient (oral) drugs for the treatment of a wide range of diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772681754508 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ventyx Biosciences (VTYX)
Ventyx is a clinical-stage biotech company developing small molecules to treat immune diseases (psoriasis, Crohn's disease). This graph is negative. All capital is spent on R&D and clinical trials. The research staff does not generate revenue but works on developing future drugs.
%20Chart%20Ventyx%20Biosciences%20(VTYX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ventyx-Biosciences-VTYX&v=1772681754518 "Company Profit Per Employee (in thousands of dollars) Chart Ventyx Biosciences (VTYX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Ventyx Biosciences is a biotech company specializing in the development of oral (tablet-based) drugs for the treatment of a wide range of immune diseases, such as psoriasis and Crohn's disease. This chart represents an industry benchmark. For biotech R&D companies, it serves as a benchmark, demonstrating the potential profitability the sector aspires to if their patient-friendly drugs are successful.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772681754528 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Ventyx Biosciences is a clinical-stage biotech company focused on developing oral (tablet-based) drugs for the treatment of autoimmune diseases (Crohn's disease, psoriasis). This is R&D. The chart shows the R&D investment (negative return) per scientist working to create a convenient alternative to injectables.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772681754541 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ventyx Biosciences (VTYX)
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs for the treatment of autoimmune diseases. This chart reflects the clinical trial stage. Potentially high future revenue per employee will result from the successful commercialization of its drugs targeting major markets such as psoriasis and Crohn's disease.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ventyx-Biosciences-VTYX&v=1772681754549 "Sales chart per company employee Ventyx Biosciences (VTYX)")
Sales per employee in the market segment - Pharma immune
Ventyx Biosciences (VTYX) is a clinical-stage biotech developing small molecules for the treatment of autoimmune diseases (psoriasis, Crohn's disease). They have no commercial revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in zero revenue per employee compared to the industry average.
Sales per employee for the market as a whole
Ventyx Biosciences is a biotech company developing oral (tablet-based) medications for the treatment of a wide range of autoimmune diseases (psoriasis, Crohn's disease). This is a pure R&D business. This graph will likely show zero revenue, as their research team is in the clinical trials phase.
Short shares by company, segment and market as a whole
Shares shorted by company Ventyx Biosciences (VTYX)
Ventyx (VTYX) is a clinical-stage biotech developing small-molecule drugs (tablets) for the treatment of a wide range of immune diseases (psoriasis, Crohn's disease). This chart shows bearish bets. The high short interest reflects investor concerns following recent clinical trial failures or doubts about the ability of their drugs to compete with existing ones.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ventyx-Biosciences-VTYX&v=1772681754599 "Short Shares Chart for the Company Ventyx Biosciences (VTYX)")
Shares shorted by market segment - Pharma immune
Ventyx (VTYX) is a biotech company developing small-molecule drugs for the treatment of autoimmune diseases such as psoriasis and Crohn's disease. This chart illustrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about the risks of clinical trials.
Shares shorted by the overall market
Ventyx Biosciences (VTYX) is a clinical-stage biotech. Its value reflects its hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require constant refinancing for R&D, and VTYX is caught in the middle of this sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ventyx Biosciences (VTYX)
Ventyx Biosciences is a biotech company operating in the competitive field of immunology (Crohn's disease, psoriasis). This chart measures the level of hype. It shows when the euphoria from trial data (overbought) or doubts about their R&D platform (oversold) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ventyx-Biosciences-VTYX&v=1772681754650 "RSI 14 indicator chart for the company's stock Ventyx Biosciences (VTYX)")
RSI 14 Market Segment - Pharma immune
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing oral (tablet) therapies for the treatment of a wide range of autoimmune and inflammatory diseases (psoriasis, Crohn's disease). This chart reflects the overall sentiment in the biotech sector and helps assess how the market views this speculative industry.
RSI 14 for the overall market
Ventyx (VTYX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VTYX (Ventyx Biosciences)
Ventyx (VTYX) is a biotech company developing oral (tablet) therapies for the treatment of autoimmune diseases such as psoriasis and Crohn's disease. This chart shows the average target price, reflecting analysts' opinions on the potential of its candidates in the highly competitive immunology market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VTYX-Ventyx-Biosciences&v=1772681754669 "A chart showing analyst consensus forecasts for the expected stock price. VTYX (Ventyx Biosciences)")
The difference between the consensus estimate and the actual stock price VTYX (Ventyx Biosciences)
Ventyx Biosciences is a biotech company developing oral (tablet) therapies for a wide range of autoimmune diseases, such as psoriasis. This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in their clinical development pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VTYX-Ventyx-Biosciences&v=1772681754691 "A chart showing the difference between the consensus forecast and the actual stock price. VTYX (Ventyx Biosciences)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Ventyx Biosciences is a clinical-stage biotech company developing oral medications (tablets) for the treatment of complex immune diseases (psoriasis, Crohn's disease). This chart shows analysts' overall expectations for the immunotherapy sector. It reflects whether experts believe oral medications will be successful versus injections in this competitive field.
Analysts' consensus forecast for the overall market share price
Ventyx Biosciences is a clinical-stage biotech company developing oral (tablet) drugs for the treatment of complex autoimmune diseases (Crohn's disease, psoriasis). This chart shows overall market sentiment. For Ventyx, as an R&D company, it's important to understand how overall risk appetite (sentiment) influences funding for their competitive race. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biotech company. They develop oral medications (tablets), rather than injections, to treat a wide range of autoimmune and inflammatory diseases, such as psoriasis, Crohn's disease, and lupus. This chart is a clear indicator of faith in their science. It reflects the market's assessment of their clinical data and the potential of their small molecules in this multi-billion-dollar niche.
AKIMA Market Segment Index - Pharma immune
Ventyx Biosciences is a biopharmaceutical company developing small-molecule drugs to treat a wide range of autoimmune diseases, such as psoriasis and Crohn's disease. This chart shows the average index for the immunopharmaceutical sector. It helps investors assess how Ventyx's performance compares to the industry average for companies exploring new treatment options.
The AKIM Index for the overall market
Ventyx Biosciences is a biotech company developing oral medications for immune and inflammatory diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is rethinking its pipeline after clinical failures, stacks up against overall economic trends.
